Mineralys Therapeutics (MLYS) Enterprise Value (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Enterprise Value of -$644.9 million for Q1 2026, up 1.78% sequentially from -$656.6 million in Q4 2025, and down 88.02% YoY from -$5.4 billion in Q1 2025.
Mineralys Therapeutics (MLYS) Enterprise Value (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Enterprise Value for 5 years, with the latest figure at -$644.9 million in Q1 2026.
- Quarterly Enterprise Value fell 88.02% year-over-year to -$644.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$644.9 million (down 88.02% YoY) and the FY2025 annual result came in at -$656.6 million, down 231.32% from the prior year.
- Enterprise Value climbed to -$644.9 million in Q1 2026 per MLYS's latest filing, from -$656.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$110.1 million in Q4 2022 and troughed at -$656.6 million in Q4 2025.
- A 5-year average of -$342.4 million and a median of -$289.4 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value rose 16.22% in 2024, then sank 231.32% in 2025.
- Over 5 years, Enterprise Value stood at -$110.1 million in 2022, then plunged by 114.85% to -$236.6 million in 2023, then grew by 16.22% to -$198.2 million in 2024, then tumbled by 231.32% to -$656.6 million in 2025, then rose by 1.78% to -$644.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$644.9 million, -$656.6 million, and -$593.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | -661.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -661.41 Mn |
| Mar 31, 2026 | -644.93 Mn |
| Dec 31, 2025 | -656.64 Mn |
| Sep 30, 2025 | -593.63 Mn |
| Jun 30, 2025 | -323.88 Mn |
| Mar 31, 2025 | -343.01 Mn |
| Dec 31, 2024 | -198.19 Mn |
| Sep 30, 2024 | -263.60 Mn |
| Jun 30, 2024 | -311.02 Mn |
| Mar 31, 2024 | -338.57 Mn |
| Dec 31, 2023 | -236.57 Mn |
| Sep 30, 2023 | -252.41 Mn |
| Jun 30, 2023 | -253.46 Mn |
| Mar 31, 2023 | -267.73 Mn |
| Dec 31, 2022 | -110.11 Mn |